Sun Pharmaceutical Industries Limited (IN:SUNPHARMA)
:SUNPHARMA
Want to see IN:SUNPHARMA full AI Analyst Report?
SUNPHARMA Stock Chart & Stats
₹1730.15
-₹15.65(-0.84%)
At close: 4:00 PM EST
₹1730.15
-₹15.65(-0.84%)
Day’s Range― - ―
52-Week Range₹1,547.25 - ₹1,850.95
Previous CloseN/A
Volume1.30M
Average Volume (3M)102.58K
Market Cap
₹3.89T
Enterprise Value₹4.12T
Total Cash (Recent Filing)₹278.80B
Total Debt (Recent Filing)₹52.15B
Price to Earnings (P/E)30.6
Beta0.55
Next Earnings
May 21, 2026EPS Estimate
11.34Next Dividend Ex-DateN/A
Dividend Yield0.91%
Share Statistics
EPS (TTM)14.70
Shares Outstanding2,399,278,300
10 Day Avg. Volume56,056
30 Day Avg. Volume102,581
Financial Highlights & Ratios
PEG Ratio2.61
Price to Book (P/B)5.64
Price to Sales (P/S)7.74
P/FCF Ratio34.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,916.33Price Target Upside10.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)56.18
Revenue Forecast (FY)₹646.96B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSun Pharma's operating cash flow exceeds reported net income and free cash flow grew 20.2% year-over-year. This durable cash conversion capacity supports sustained funding for R&D, capex, dividends or M&A without relying on external financing, improving long-term financial flexibility.
Very Low Leverage And Solid Balance SheetExtremely low debt levels and improved ROE reflect conservative capital structure and efficient capital use. This reduces interest and refinancing risk, preserves capacity for strategic investments or acquisitions, and provides a buffer through industry cycles for durable operational continuity.
Diversified Business Model Across Markets And SegmentsA multi-pronged model—branded generics in emerging markets, generics in regulated markets, and specialty/complex therapies—provides durable revenue diversification. Specialty and geographic breadth reduce reliance on any single market and enable mix management to protect margins over the medium term.
Bears Say
Exposure To Generics Pricing PressureSignificant exposure to commoditized generics, especially in the U.S., subjects core revenue to structural price erosion and customer consolidation. Over months to years, persistent pricing competition can compress margins and force continual new launches to sustain growth.
Gross Margin ContractionA material decline in gross margin suggests rising COGS or a shift toward lower-margin products/markets. Even with net margin gains, sustained gross margin pressure can limit future operating leverage and make margin improvement more dependent on cost cuts or higher-margin product mix changes.
Negative EPS Growth MetricA negative EPS growth indicator points to recent earnings volatility or dilution that may persist. For investors seeking steady earnings expansion, this suggests potential variability in profitability drivers—product cycles, one-offs, or pricing—which can limit reliably improving per-share returns.
Sun Pharmaceutical Industries Limited News
SUNPHARMA FAQ
What was Sun Pharmaceutical Industries Limited’s price range in the past 12 months?
Sun Pharmaceutical Industries Limited lowest stock price was ₹1547.25 and its highest was ₹1850.95 in the past 12 months.
What is Sun Pharmaceutical Industries Limited’s market cap?
Sun Pharmaceutical Industries Limited’s market cap is ₹3.89T.
When is Sun Pharmaceutical Industries Limited’s upcoming earnings report date?
Sun Pharmaceutical Industries Limited’s upcoming earnings report date is May 21, 2026 which is in 22 days.
How were Sun Pharmaceutical Industries Limited’s earnings last quarter?
Sun Pharmaceutical Industries Limited released its earnings results on Jan 31, 2026. The company reported ₹14.7 earnings per share for the quarter, beating the consensus estimate of ₹12.909 by ₹1.791.
Is Sun Pharmaceutical Industries Limited overvalued?
According to Wall Street analysts Sun Pharmaceutical Industries Limited’s price is currently Undervalued.
Does Sun Pharmaceutical Industries Limited pay dividends?
Sun Pharmaceutical Industries Limited pays a Semiannually dividend of ₹5.5 which represents an annual dividend yield of 0.91%. See more information on Sun Pharmaceutical Industries Limited dividends here
What is Sun Pharmaceutical Industries Limited’s EPS estimate?
Sun Pharmaceutical Industries Limited’s EPS estimate is 11.34.
How many shares outstanding does Sun Pharmaceutical Industries Limited have?
Sun Pharmaceutical Industries Limited has 2,399,278,300 shares outstanding.
What happened to Sun Pharmaceutical Industries Limited’s price movement after its last earnings report?
Sun Pharmaceutical Industries Limited reported an EPS of ₹14.7 in its last earnings report, beating expectations of ₹12.909. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sun Pharmaceutical Industries Limited?
Currently, no hedge funds are holding shares in IN:SUNPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology and ophthalmic, neuro-psychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances; generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.
SUNPHARMA Stock 12 Month Forecast
Average Price Target
₹1,916.33
▲(10.76% Upside)
Technical Analysis
Cipla Ltd
―
Divi's Laboratories Limited
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Torrent Pharmaceuticals Ltd
―